MedPath

Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

Phase 2
Completed
Conditions
Pancreatic Cancer
Registration Number
NCT00335543
Lead Sponsor
Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet know whether giving chemotherapy together with radiation therapy before surgery is more effective than surgery alone in treating pancreatic cancer.

PURPOSE: This randomized phase II trial is studying how well giving gemcitabine and cisplatin together with radiation therapy before surgery works compared to surgery alone in treating patients with localized pancreatic cancer that can be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

* Determine whether neoadjuvant chemoradiotherapy comprising gemcitabine hydrochloride, cisplatin, and radiotherapy is better than immediate surgery, in terms of median survival, in patients with locally resectable adenocarcinoma of the pancreatic head.

Secondary

* Compare 3-year survival rate in patients treated with these regimens.

* Compare R0 resection rate in these patients.

* Compare the rate of medium and high toxicity events in these patients.

* Compare the rate of complete and incomplete remission of the tumor as measured by radiographic imaging studies.

* Compare the rate of different regression gradings in resected tumor specimens.

* Compare the quality of life of these patients.

OUTLINE: This is a prospective, randomized, controlled, open-label, multicenter study. Patients are stratified according to participating center and staging laparoscopy (yes vs no). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 22, and 29. Patients also undergo radiotherapy to the tumor and surrounding lymph nodes 5 days a week for 5 weeks followed by 3 more doses of radiotherapy directly to the tumor. Approximately 6 weeks after finishing chemoradiotherapy, patients with no evidence of disease progression undergo surgery to remove the tumor.

* Arm II: Patients undergo surgery to remove the tumor. After surgery, all patients receive adjuvant chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, at the end of chemotherapy and before surgery (arm I), and then at 6 weeks, 6 months, 12 months, and 24 months after surgery.

After completion of study treatment, patients are followed every 3 months for 2 years and then at 3 years.

PROJECTED ACCRUAL: A total of 254 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
254
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Median survival
Secondary Outcome Measures
NameTimeMethod
3-year survival rate
R0 resection rate
Rate of medium and high toxicity events
Rate of complete and incomplete remission of the tumor as measured by radiographic imaging studies
Rate of different regression gradings in resected tumor specimens
Quality of life before, during, and after therapy

Trial Locations

Locations (17)

Allgemeines Krankenhaus - Universitatskliniken

🇦🇹

Vienna, Austria

Robert Roessle Comprehensive Cancer Center - Charite Campus Buch

🇩🇪

Berlin, Germany

Universitaet Leipzig

🇩🇪

Leipzig, Germany

Staedtisches Klinikum Magdeburg

🇩🇪

Magdeburg, Germany

Klinikum der Universitaet Regensburg

🇩🇪

Regensburg, Germany

Klinik am Eichert

🇩🇪

Goeppingen, Germany

Innsbruck Universitaetsklinik

🇦🇹

Innsbruck, Austria

Klinikum Nuernberg - Klinikum Nord

🇩🇪

Nuremberg, Germany

Knappschaft Krankenhaus

🇩🇪

Bochum, Germany

Universitaet Erlangen

🇩🇪

Erlangen, Germany

DIAKO Ev. Diakonie Krankenhaus gGmbH

🇩🇪

Bremen, Germany

Krankenhaus Dresden - Friedrichstadt

🇩🇪

Dresden, Germany

Universitaetsklinikum Tuebingen

🇩🇪

Tuebingen, Germany

Arbeitsgruppe Lebermetastasen und Tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie

🇩🇪

Frankfurt, Germany

Chirurgische Universitaetsklinik

🇩🇪

Heidelberg, Germany

Klinikum der Universitaet Muenchen - Grosshadern Campus

🇩🇪

Munich, Germany

Kantonsspital - St. Gallen

🇨🇭

St. Gallen, Switzerland

© Copyright 2025. All Rights Reserved by MedPath